Австралия - английский - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.07 mg (equivalent: estradiol, qty 2 mg); norethisterone acetate, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; hyprolose; purified talc; magnesium stearate; hypromellose; triacetin - short term symptomatic treatment of postmenopausal oestrogen deficiency (see dosage and administration and clinical trials). for the prevention of postmenopausal bone mineral density loss. when prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of kliogest should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing. see precautions and dosage and administration. kliogest is for use in postmenopausal women with an intact uterus. in perimenopausal women treated with kliogest the incidence of vaginal bleeding is unacceptably high and therefore therapy should not be initiated sooner than one year after the last menstrual period.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate; microcrystalline cellulose; hypromellose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; iron oxide yellow; macrogol 400 - for the treatment of postmenopausal women with hormone receptor positive breast cancer (see clinical trials). the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Сингапур - английский - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - dydrogesterone, micronized (in grey tablet); estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in grey tablet); estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in white tablet) - tablet, film coated - 10 mg - dydrogesterone, micronized (in grey tablet) 10 mg; estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in grey tablet) 1 mg; estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in white tablet) 1 mg

Австралия - английский - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol hemihydrate, quantity: 1.033 mg (equivalent: estradiol, qty 1 mg); drospirenone, quantity: 2 mg - tablet, film coated - excipient ingredients: povidone; hypromellose; magnesium stearate; lactose monohydrate; purified talc; macrogol 6000; titanium dioxide; pregelatinised maize starch; maize starch; iron oxide red - hormone replacement therapy (hrt) for use in the short-term treatment in postmenopausal women with an intact uterus of the climacteric syndrome caused by deficient endogenous oestrogen production due to natural menopause, hypogonadism, castration or primary ovarian failure.

Сингапур - английский - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - (blue tablet) estradiol hemihydrate 2.07mg equivalent to; (red tablet) estradiol hemihydrate 1.03mg equivalent to; (white tablet) estradiol as hemihydrate 2.07mg equivalent to; (white tablet) norethisterone acetate - tablet, film coated - 2 mg - (blue tablet) estradiol hemihydrate 2.07mg equivalent to 2 mg; (red tablet) estradiol hemihydrate 1.03mg equivalent to 1 mg; (white tablet) estradiol as hemihydrate 2.07mg equivalent to 2 mg; (white tablet) norethisterone acetate 1 mg

Австралия - английский - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; sodium starch glycollate; iron oxide yellow; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - treatment of postmenopausal women with hormone receptor positive breast cancer (see "clinical trials"). the safety and efficacy of neoadjuvant use has not been established. letrozole is not indicated in hormone receptor negative disease.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; sodium starch glycollate type a; colloidal anhydrous silica; hypromellose; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; macrogol 400 - indicated for the treatment of post menopausal women with hormone receptor positive breast cancer. . the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: iron oxide yellow; lactose monohydrate; sodium starch glycollate; hypromellose; macrogol 8000; colloidal anhydrous silica; maize starch; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc - for the treatment of postmenopausal women with hormone receptor positive breast cancer (see clinical trials). the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

actor pharmaceuticals pty ltd - tibolone, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; ascorbyl palmitate; magnesium stearate; potato starch - indications ? short-term treatment of symptoms resulting from the natural or surgical menopause in postmenopausal women.,? second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss.,after careful selection of users, tibogen should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer clinical trials and precautions). tibogen should only be continued for as long as the benefit outweighs the risks.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate; maize starch; magnesium stearate; lactose monohydrate; titanium dioxide; macrogol 8000; hypromellose; triacetin; iron oxide yellow; iron oxide red; quinoline yellow aluminium lake; polydextrose - for the treatment of postmenopausal women with hormone receptor positive breast cancer. the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.